MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
Recent Press Releases
08/09/16MyoKardia Reports Second Quarter 2016 Financial Results and Continued Progress on Clinical Programs
07/14/16SHaRe Registry Data Published in PNAS Demonstrate the Power of Combining Clinical, Genetic and Structural Data to Gain Insight into Hypertrophic Cardiomyopathy
NASDAQ GS | MYOK (Common Stock)
$21.03 + 0.38
08/24/164:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.